Elite Pharmaceuticals, Inc. (ELTP)
OTCMKTS · Delayed Price · Currency is USD
0.3649
+0.0072 (2.01%)
Aug 7, 2026, 2:04 PM EST
Elite Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 385 | 388 | 465 | 157 | 29 | 35 | |
Market Cap Growth | -33.05% | -16.54% | 195.83% | 434.24% | -16.81% | -42.59% |
Enterprise Value | 361 | 373 | 468 | 159 | 27 | 31 |
Last Close Price | 0.36 | 0.36 | 0.43 | 0.15 | 0.03 | 0.03 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 11.92 | 8.64 | - | 7.81 | 8.26 | 3.97 |
PS Ratio | 2.59 | 2.61 | 5.53 | 2.77 | 0.86 | 1.10 |
PB Ratio | 3.90 | 3.92 | 8.68 | 2.73 | 1.01 | 1.40 |
P/TBV Ratio | 3.90 | 3.92 | 8.73 | 2.74 | 1.03 | 1.43 |
P/FCF Ratio | 16.88 | 16.99 | 79.70 | - | - | 5.88 |
P/OCF Ratio | 16.22 | 16.33 | 62.33 | - | 8.81 | 5.43 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 2.43 | 2.50 | 5.56 | 2.81 | 0.80 | 0.96 |
EV/EBITDA Ratio | 6.93 | 7.24 | 20.43 | 13.09 | 5.25 | 4.94 |
EV/EBIT Ratio | 7.23 | 7.46 | 22.05 | 14.75 | 6.92 | 6.11 |
EV/FCF Ratio | 15.83 | 16.33 | 80.19 | - | - | 5.15 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.06 | 0.06 | 0.20 | 0.20 | 0.13 | 0.11 |
Debt / EBITDA Ratio | 0.11 | 0.11 | 0.46 | 0.95 | 0.73 | 0.43 |
Debt / FCF Ratio | 0.26 | 0.26 | 1.87 | - | - | 0.46 |
Net Debt / Equity Ratio | -0.24 | -0.24 | -0.01 | 0.08 | -0.14 | -0.23 |
Net Debt / EBITDA Ratio | -0.47 | -0.47 | -0.02 | 0.38 | -0.75 | -0.92 |
Net Debt / FCF Ratio | -1.05 | -1.05 | -0.07 | -1.14 | 1.65 | -0.96 |
Asset Turnover | 1.27 | 1.27 | 0.93 | 0.91 | 0.90 | 1.05 |
Inventory Turnover | 3.94 | 3.94 | 3.01 | 2.69 | 2.16 | 2.97 |
Quick Ratio | 5.15 | 5.15 | 3.42 | 2.04 | 1.40 | 1.73 |
Current Ratio | 6.45 | 6.45 | 4.88 | 3.07 | 2.75 | 2.82 |
Return on Equity (ROE) | 58.89% | 58.89% | -7.77% | 46.47% | 13.15% | 43.01% |
Return on Assets (ROA) | 26.61% | 26.61% | 14.72% | 10.83% | 6.52% | 10.33% |
Return on Invested Capital (ROIC) | 56.30% | 61.65% | 36.77% | 24.74% | 15.95% | 29.14% |
Return on Capital Employed (ROCE) | 41.30% | 41.30% | 25.10% | 15.30% | 12.00% | 17.80% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 11.65% | 11.57% | -0.93% | 12.80% | 12.11% | 25.18% |
FCF Yield | 5.92% | 5.88% | 1.26% | -2.57% | -8.15% | 17.00% |
Buyback Yield / Dilution | -6.56% | -6.56% | -4.40% | -1.02% | -0.23% | -7.17% |